Demir et al. demonstrated increased APR-246 efficacy in mutant TP53 ALL cell lines and patient-derived ALL xenografts in mice [32], in line with many of our previous studies showing that cancer cells with mutant TP53 are more sensitive to APR-246 than wild-type TP53 cells [6, 7, 11, 39]. Here, TP53 is linked to cancer.